Michel Delforge, MD, PhD from the University Hospital Leuven, Leuven, Belgium gives an overview of the mechanism of action of proteasome inhibitors. Prof Delforge gives a detailed outline of how the proteasome is targeted. He further discusses the different classes of proteasome inhibitors, i.e. the boronic acid derivatives (bortezomib, ixazomib), epoxyketone derivatives (carfilzomib, oprozomib) and salinosporamide derivatives (marizomib). Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.